| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary targets of effusol include inflammatory mediators such as COX-2, iNOS, and pro-inflammatory cytokines. The compound inhibits the activation of NF-κB and MAPK signaling pathways, which are involved in the production of inflammatory mediators. Effusol also exhibits antioxidant activity by scavenging free radicals and upregulating antioxidant enzymes. Its neuroprotective effects may involve the modulation of oxidative stress and inflammatory pathways in the central nervous system.
|
|---|---|
| ln Vitro |
In vitro studies have shown that effusol possesses significant anti-inflammatory activity by reducing the production of nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in stimulated macrophages. The compound inhibits the expression of COX-2 and iNOS by blocking NF-κB and MAPK signaling pathways. Effusol also exhibits antioxidant activity by scavenging DPPH and ABTS free radicals and protecting cells from oxidative stress-induced damage.
|
| ln Vivo |
In vivo studies in animal models have demonstrated the anti-inflammatory and neuroprotective effects of effusol. In models of acute inflammation, effusol reduces edema and inflammatory cell infiltration. In models of neuroinflammation, the compound attenuates the activation of microglia and the production of inflammatory mediators. Effusol has also shown protective effects in models of neurodegenerative diseases, reducing neuronal damage and improving behavioral outcomes.
|
| Enzyme Assay |
Non-cellular assays for effusol typically involve measuring its antioxidant activity using DPPH, ABTS, or FRAP assays. The compound's ability to scavenge free radicals is quantified by measuring the reduction in absorbance at specific wavelengths. Inhibition of COX-2 and iNOS enzyme activities can be assessed using enzyme activity assays. These cell-free systems allow for precise characterization of the compound's biochemical properties.
|
| Cell Assay |
Cellular assays for effusol are conducted using macrophage cell lines such as RAW 264.7 to assess its anti-inflammatory activity. Cells are stimulated with LPS to induce inflammation, and the compound's effects on NO production (Griess assay), cytokine production (ELISA), and expression of inflammatory mediators (Western blotting, qPCR) are assessed. Neuroprotective effects are evaluated in neuronal cell lines or primary neurons exposed to oxidative stress or inflammatory insults.
|
| Animal Protocol |
In vivo animal experiments for effusol typically use rodent models of inflammation or neurological disorders. For anti-inflammatory studies, the compound is administered orally or intraperitoneally before or after the induction of inflammation. Edema, inflammatory cell infiltration, and cytokine levels are assessed. For neuroprotective studies, the compound is administered in models of stroke, traumatic brain injury, or neurodegenerative diseases, and neuronal damage and behavioral outcomes are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of effusol have not been extensively characterized. As a lipophilic phenanthrene compound, it may have good oral bioavailability and the ability to cross the blood-brain barrier. The compound's metabolism and elimination pathways have not been fully elucidated. Standard formulation approaches for lipophilic natural products may be applicable. Further pharmacokinetic studies are needed to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Toxicological data for effusol are limited, as it is a natural product research compound. No significant toxicity has been reported in the available literature. The compound is derived from a plant used in traditional medicine, suggesting a favorable safety profile. However, comprehensive toxicological studies are needed to establish its safety margin. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
According to reports, Effusol is found in Juncus effusus, Juncus effusus, and Juncus effusus, and there is available data on its content.
Other information includes effusol's presence in Juncus effusus, a plant used in traditional Asian medicine for treating various ailments including inflammation, fever, and neurological disorders. The compound is one of several bioactive phenanthrenes isolated from this plant. Effusol has been studied for its potential therapeutic applications in inflammatory diseases, neurodegenerative disorders, and cancer. It remains a research compound with no approved clinical indications. |
| Molecular Formula |
C17H16O2
|
|---|---|
| Molecular Weight |
252.31
|
| Exact Mass |
252.115
|
| CAS # |
73166-28-6
|
| PubChem CID |
100801
|
| Appearance |
White to off-white solid
|
| Density |
1.229g/cm3
|
| Boiling Point |
508.9ºC at 760 mmHg
|
| Flash Point |
248.4ºC
|
| Index of Refraction |
1.684
|
| LogP |
3.814
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
340
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=CC2=C1CCC3=C2C(=CC(=C3)O)C=C)O
|
| InChi Key |
GEXAPRXWKRZPCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H16O2/c1-3-11-8-13(18)9-12-4-5-14-10(2)16(19)7-6-15(14)17(11)12/h3,6-9,18-19H,1,4-5H2,2H3
|
| Chemical Name |
5-ethenyl-1-methyl-9,10-dihydrophenanthrene-2,7-diol
|
| Synonyms |
Effusol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9634 mL | 19.8169 mL | 39.6338 mL | |
| 5 mM | 0.7927 mL | 3.9634 mL | 7.9268 mL | |
| 10 mM | 0.3963 mL | 1.9817 mL | 3.9634 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
